CLINICAL AND PATHOGENETIC ASPECTS OF ISCHAEMIC HEART DISEASE COMPLICATED BY CHTONIC HEART FAILURE

Cover Page

Abstract


Objectives: To investigate genetic and neurohumoral determinants of chronic heart failure (CHF) development and progression in ischaemic heart disease (IHD) patients. Methods: Serum neurohormone level analysis (angiotensin II, aldosterone, endotheline1, NTproBNP, TNFα) and genotyping (genes encoding ACE, angiotensinogen, and type1 angiotensin II receptors ) were implemented in 100 patients Results: Activation of endotheline and NTproBNP is characteristic of early CHF stages while decompensation of chronic heart failure shows elevation in aldosterone and TNFα . Structural polymorphism of renineangiotensine system genes is not significant in CHF development and progression in IHD patients.

Full Text

КЛИНИКО-ПАТОГЕНЕТИЧЕСКИЕ АСПЕКТЫ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА, ОСЛОЖНЕННОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ

References

  1. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХАОХСН) // Журнал сердечная недостаточность. 2004. Т. 5 (1). С. 47.
  2. Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis // Eur. Heart J. 2003. Vol. 24 (5). P. 442-463.
  3. Ho K.K., Pinsky J.L., Kannel W.B. et al. The epidemiology of heart failure: Fremigham Study // J. Am. Coll. Cardiol. 1993. Vol. 22 (suppl. A). P. 6A-13A.
  4. Bay M., Kirk V., Parner J. et al. NTproBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular sys tolic function // Heart. 2003. Vol. 89 (2). P. 150-154.
  5. Fatini C., Abbate R., Pepe G. et al. Searching for a better assessment of the individual coronary risk profile: the role of angiotensinconverting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms // Eur. Heart J. 2000. Vol. 21 (8). P. 633-638.
  6. Fuat A., Murphy J.J., Hungin A.P. et al. The diagnostic accuracy and utility of a Btype natriuretic peptide test in a community population of patients with suspected heart failure // Br. J. Gen. Pract. 2006. Vol. 56 (526). P. 327-333.
  7. Pfohl M., Koch M., Prescod S. et al. Angiotensin Iconverting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study // Eur. Heart J. 1999. Vol. 20 (18). P. 1318-1325.
  8. Katz A. Maladaptive hypertrophy and the cardiomyoparty of overload: Familial cardiomyopathies / In: Katz A. (ed.): Heart failure: Pathophysiology, molecular biology and clinical management. Philadelphia, Lippincott Williams Wilkins. 2000. P. 277-308.
  9. Latini R., Masson S., Anand I. еt al. The comparative prognostic value of plasma neurehormones at baseline in patients with heart failure enrolled in ValHeFT // Eur. Heart J. 2004. Vol. 25 (4). P. 292-299.
  10. Serneri G.G., Boddi M., Cecioni I. et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function // Circ. Res. 2001. Vol. 88 (9). P. 961-968.
  11. Zaman A.G., Helft G., Worthley S.G., Badimon J.J. The Role of plaque rupture and thrombosis in coronary artery disease // Atherosclerosis. 2000. Vol. 149 (2). P. 251-256.
  12. Groenning B.A., Nilsson J.C., Sondergaard L. et al. Detection of left ventricular enlargement and impaired systolic function with plasma Nterminal pro brain natriuretic peptide concentrations // Am. Heart J. 2002. Vol. 143 (5). P. 23-29.
  13. Maisel A.S., Koon J., Krishnaswamy P. et al. Utility of Bnatriuretic peptide as a rapid, pointofcare test for screening patients undergoing echocardiography to determine left ventricular dysfunction // Am. Heart J. 2001. Vol. 141 (3). P. 367-374.
  14. McDonagh T.A., Cunningham A.D., Morrison C.E. et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population // Heart. 2001. Vol. 86 (l). P. 21-26.
  15. Gardner R.S., Ozalp F., Murday A.J. et al. Nterminal probrain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure // Eur. Heart J. 2003. Vol. 24 (19). P. 1735-1743.
  16. Gustafsson F., Badskj J., Hansen F.S. et al. Value of Nterminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography // Heart Drug. 2003. Vol. 3. P. 141-146.
  17. Feldman A.M., Combes A., Wagner D. et al. The role of tumor necrosis factor in the pathophysiology of heart failure // Am. Col. Cardiol. 2000. Vol. 35 (3). P. 537-544.
  18. Терещенко С.Н., Джаиани Н.А., Моисеев В.С. Генетические аспекты хронической сердечной недостаточности // Тер. арх. 2000. Т. 72 (4). С. 75-77.
  19. Шляхто Е.В., Конради А.О. Блокирование ренинангиотензиновой системы при артериальной гипертензии: фармакогенетический подход // Артериальная гипертензия. 2002. Т. 4 (3). С. 24-27.

Statistics

Views

Abstract - 247

PDF (Russian) - 129

Cited-By


Article Metrics

Metrics Loading ...

PlumX


Copyright (c) 2011 Dorofeeva N.P., Pleskachev S.A., Shlyk S.V., Tchigaeva E.V., TherAnanyanz E.A., Mashtalova O.G., Koulikova I.E., Pleskachev A.S., Todorov S.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies